IS7613A - Pramípexól í skammtaformi sem gefið er einu sinniá dag - Google Patents

Pramípexól í skammtaformi sem gefið er einu sinniá dag

Info

Publication number
IS7613A
IS7613A IS7613A IS7613A IS7613A IS 7613 A IS7613 A IS 7613A IS 7613 A IS7613 A IS 7613A IS 7613 A IS7613 A IS 7613A IS 7613 A IS7613 A IS 7613A
Authority
IS
Iceland
Prior art keywords
once daily
dose administration
pramipexole
pramipexole once
dose
Prior art date
Application number
IS7613A
Other languages
English (en)
Inventor
J. Lee Ernest
M. Bredael Gerard
R. Baldwin John
R. Cox Steven
J. Heintz Mark
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31192088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of IS7613A publication Critical patent/IS7613A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7613A 2002-07-25 2004-12-23 Pramípexól í skammtaformi sem gefið er einu sinniá dag IS7613A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25
US39844702P 2002-07-25 2002-07-25
US47951403P 2003-06-18 2003-06-18
PCT/US2003/023522 WO2004010999A1 (en) 2002-07-25 2003-07-25 Pramipexole once-daily dosage form

Publications (1)

Publication Number Publication Date
IS7613A true IS7613A (is) 2004-12-23

Family

ID=31192088

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7613A IS7613A (is) 2002-07-25 2004-12-23 Pramípexól í skammtaformi sem gefið er einu sinniá dag

Country Status (40)

Country Link
US (2) US8679533B2 (is)
EP (2) EP1536792B1 (is)
JP (1) JP4607584B2 (is)
KR (2) KR101066374B1 (is)
CN (1) CN1671381B (is)
AP (1) AP2223A (is)
AR (1) AR040682A1 (is)
AU (1) AU2003256921B2 (is)
BR (1) BR0312948A (is)
CA (1) CA2493629C (is)
CU (1) CU23468B7 (is)
CY (2) CY1114263T1 (is)
DE (1) DE20321906U1 (is)
DK (2) DK2289514T5 (is)
EA (1) EA017595B1 (is)
EC (1) ECSP055569A (is)
ES (2) ES2436745T3 (is)
GE (1) GEP20074047B (is)
HK (1) HK1078007A1 (is)
HR (1) HRP20041234B1 (is)
IL (1) IL166076A0 (is)
IS (1) IS7613A (is)
MA (1) MA27372A1 (is)
ME (1) ME00347B (is)
MX (1) MXPA05000980A (is)
MY (1) MY142204A (is)
NO (1) NO20050481L (is)
NZ (1) NZ562681A (is)
OA (1) OA12889A (is)
PA (1) PA8578501A1 (is)
PE (1) PE20040134A1 (is)
PL (1) PL375444A1 (is)
PT (2) PT1536792E (is)
RS (1) RS52764B (is)
SG (1) SG177011A1 (is)
SI (2) SI1536792T1 (is)
TW (1) TWI351955B (is)
UY (1) UY27913A1 (is)
WO (1) WO2004010999A1 (is)
ZA (1) ZA200500015B (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US7365086B2 (en) * 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
MX2007001850A (es) * 2004-08-13 2007-03-28 Boehringer Ingelheim Int Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo.
EP1781260B2 (en) * 2004-08-13 2014-04-02 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CN101031322A (zh) * 2004-10-01 2007-09-05 日本脏器制药株式会社 固体药物制剂
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CA2688074A1 (en) * 2007-05-25 2008-12-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation comprising pramipexole
WO2008150741A1 (en) * 2007-06-04 2008-12-11 Drugtech Corporation Controlled release dopamine agonist compositions
US20090304794A1 (en) * 2008-06-09 2009-12-10 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20120021057A1 (en) * 2009-04-09 2012-01-26 Purdue Pharma Once-daily oral ir/cr pramipexole formulation
CA2767029A1 (en) * 2009-07-02 2011-01-06 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
WO2011086182A2 (en) * 2010-01-18 2011-07-21 Synthon Bv Pramipexole extended release tablets
TR201001862A1 (tr) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
WO2011128914A2 (en) 2010-04-15 2011-10-20 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
AU2011256928A1 (en) 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
CN102670550A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸普拉克索渗透泵型控释片
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
CN102406626B (zh) * 2011-12-02 2013-08-28 深圳海王药业有限公司 盐酸普拉克索缓释片剂及其制备方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
CN104744400B (zh) * 2012-11-22 2017-08-11 北京三泉医药技术有限公司 用于治疗神经疾病的四氢苯并噻唑衍生物
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CN104606162B (zh) * 2015-01-07 2017-03-29 海南康虹医药科技开发有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CN104784155B (zh) * 2015-05-15 2018-02-23 中国药科大学 一种盐酸普拉克索组合微丸胶囊及其制备方法
CN105030721B (zh) * 2015-08-30 2018-05-04 南京康川济医药科技有限公司 一种含有盐酸普拉克索的口服固体组合物
JP6978417B2 (ja) * 2016-10-07 2021-12-08 トランスウェル・バイオテック・カンパニー・リミテッド プラミペキソール経皮送達系及びその使用
MX2019007128A (es) * 2016-12-21 2019-09-19 Hso Herbert Schmidt Gmbh & Co Kg Solucion de decapado para decapar materiales sinteticos.
CA3097332A1 (en) * 2017-04-24 2018-11-01 Chase Therapeutics Corporation Composition comprising pramipexole and 5ht3 antagonist for treating dep ression
US11234961B2 (en) 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
NL128902C (is) 1960-06-06
US3458622A (en) 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) * 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4666612A (en) 1986-03-17 1987-05-19 Kerr-Mcgee Chemical Corporation Method for recovering a wood preservative from waste sludges
US4772473A (en) 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4859470A (en) 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
EP0447168A3 (en) 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5656296A (en) 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5661171A (en) 1992-07-02 1997-08-26 Oramed, Inc. Controlled release pilocarpine delivery system
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
DE4241013A1 (de) 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1997024109A1 (en) 1995-12-27 1997-07-10 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JPH1017497A (ja) 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
ATE322892T1 (de) 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
CA2211778A1 (en) 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
EP1019023B1 (en) 1997-09-29 2003-05-07 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
WO1999045924A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Plc Composition
EA200300124A1 (ru) 1998-05-15 2003-10-30 Фармация Энд Апджон Компани Применение прамипексола для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
JP2004500331A (ja) 1999-07-13 2004-01-08 アルファ　リサーチ　グループ，　エルエルシー パーキンソン病の処置のための組成物および方法
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
CA2384840A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
EP1225888A2 (en) 1999-10-19 2002-07-31 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating cns-mediated disorders
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MXPA02006150A (es) 1999-12-22 2004-09-06 Pharmacia Corp Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
CA2332691C (en) 2000-01-27 2007-11-27 The York Group, Inc. Death care merchandising system
PT1255547E (pt) 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6277875B1 (en) 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
IL154290A0 (en) 2000-08-08 2003-09-17 Teva Pharma Stable pergolide mesylate and process for making same
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
EP1411901B1 (en) 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Gastric retention controlled drug delivery system
FR2827872A1 (fr) 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
US20030032661A1 (en) 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
GB0125088D0 (en) 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
CA2470636A1 (en) 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US20030224050A1 (en) 2002-01-04 2003-12-04 Charles Chiao Drug delivery system for sustained delivery of glipizide
JP2005525374A (ja) 2002-03-04 2005-08-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 担体ペプチドを含有する持続放出ドラッグ製剤
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
CN1655766B (zh) 2002-04-15 2012-05-30 利洁时有限责任公司 愈创甘油醚组合药物的持续释放
US20030215498A1 (en) 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
WO2003103603A2 (en) 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine
CA2489295A1 (en) 2002-06-27 2004-01-08 Cilag Ag Spherical pellet containing a water-soluble active ingredient
CN100367960C (zh) 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
CA2488860A1 (en) 2002-07-25 2004-02-05 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2415154C (en) 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
EP1781260B2 (en) * 2004-08-13 2014-04-02 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
MX2007001850A (es) * 2004-08-13 2007-03-28 Boehringer Ingelheim Int Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo.
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1886665A1 (en) * 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo

Also Published As

Publication number Publication date
AP2005003206A0 (en) 2005-03-31
MA27372A1 (fr) 2005-06-01
CY1114566T1 (el) 2016-10-05
SI1536792T1 (sl) 2013-11-29
CN1671381B (zh) 2010-10-27
KR101066374B1 (ko) 2011-09-20
EP1536792B1 (en) 2013-09-18
ECSP055569A (es) 2005-04-18
US20140141079A1 (en) 2014-05-22
CY1114263T1 (el) 2016-08-31
PT1536792E (pt) 2013-12-02
MY142204A (en) 2010-10-29
EP1536792A1 (en) 2005-06-08
US20050175691A1 (en) 2005-08-11
EP2289514A1 (en) 2011-03-02
DK2289514T3 (da) 2013-08-05
JP4607584B2 (ja) 2011-01-05
BR0312948A (pt) 2005-06-14
MEP52208A (en) 2011-02-10
TWI351955B (en) 2011-11-11
PL375444A1 (en) 2005-11-28
PA8578501A1 (es) 2005-02-04
ES2421787T9 (es) 2013-11-06
HK1078007A1 (en) 2006-03-03
CN1671381A (zh) 2005-09-21
DK2289514T5 (da) 2013-09-30
HRP20041234B1 (hr) 2013-07-31
EP2289514B1 (en) 2013-06-19
AP2223A (en) 2011-03-24
GEP20074047B (en) 2007-02-26
CU23468B7 (es) 2009-12-17
PT2289514E (pt) 2013-07-23
JP2005538995A (ja) 2005-12-22
CA2493629A1 (en) 2004-02-05
ME00347B (me) 2011-05-10
DK1536792T3 (da) 2013-11-11
AU2003256921B2 (en) 2009-03-05
KR20050025654A (ko) 2005-03-14
ZA200500015B (en) 2006-07-26
SG177011A1 (en) 2012-01-30
US8679533B2 (en) 2014-03-25
SI2289514T1 (sl) 2013-08-30
ES2421787T3 (es) 2013-09-05
MXPA05000980A (es) 2005-09-12
WO2004010999A1 (en) 2004-02-05
OA12889A (en) 2006-10-13
EA017595B1 (ru) 2013-01-30
IL166076A0 (en) 2006-01-15
NZ562681A (en) 2009-11-27
EP2289514B9 (en) 2013-08-21
CA2493629C (en) 2013-10-08
AU2003256921A1 (en) 2004-02-16
ES2436745T3 (es) 2014-01-07
UY27913A1 (es) 2004-02-27
DE20321906U1 (de) 2012-11-07
RS52764B (en) 2013-10-31
EA200500080A1 (ru) 2005-06-30
RS115104A (en) 2006-12-15
KR20070062614A (ko) 2007-06-15
PE20040134A1 (es) 2004-03-06
NO20050481L (no) 2005-01-27
TW200418465A (en) 2004-10-01
HRP20041234A2 (en) 2005-04-30
AR040682A1 (es) 2005-04-13

Similar Documents

Publication Publication Date Title
IS7613A (is) Pramípexól í skammtaformi sem gefið er einu sinniá dag
IS2946B (is) Lyfjablanda sem felur í sér andrógen
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
EP1567158A4 (en) METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
IS7043A (is) Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
IL171960A0 (en) Methods and compositions using immunomodulatory compound for treatment and management of cancers and other diseases
NO20034862L (no) Formulering med oksykodon for administrering en gang pr dag
HK1088543A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
IS7623A (is) Sískammtalausnar töflusamsetning úr pramipexóli
PL374832A1 (en) Novel substituted benzimidazole dosage forms and method of using same
IL165860A0 (en) Administration of therapeutic viruses
ZA200510170B (en) Method of reducing the harmful effects of orally or transdermally delivered nicotine
PL372773A1 (en) Oral administration of epothilones
EP1625111A4 (en) THYRONAMINE DERIVATIVES AND ANALOGUES AND METHODS OF USE THEREOF
ZA200500516B (en) Oral Administration of calcitonin
NO20044722L (no) Hoy dose av ibandronat formulering
SG148194A1 (en) Compositions for the treatment of affections of the oral cavity and upper respiratory tract
IS2771B (is) Filmuhúðuð tafla sem felur í sér seyði úr rauðum vínviðarlaufum
NO20050183L (no) Farmasoytiske salter av reboxetin
HK1094153A1 (en) Nasal pharmaceutical composition of piribedil
AU2003291458A8 (en) Pharmaceutical compositions and methods of using taxane derivatives
AU2003290647A8 (en) Pharmaceutical compositions and methods of using taxane derivatives
DE50313285D1 (de) Melatonin-tagesdosierungseinheiten
PT1467737E (pt) Composicao farmaceutica orodispersivel de piribedil